Genstruct Enters Into a Multi-Year Collaboration

CAMBRIDGE, Mass., Nov. 8 /PRNewswire/ -- Genstruct Inc., a knowledge-driven discovery company, announced today that it has signed an agreement with Pfizer to collaborate on a variety of research projects to help better understand complex diseases. This deal is part of a continuing, multiyear relationship Genstruct has developed with Pfizer. Terms of the partnership are not being disclosed.

This new arrangement will include research projects with several Pfizer units, including Worldwide Safety Sciences, the Proteomics Global Center of Excellence, and Clinical Sciences. Genstruct will use its Molecular Epistemics(TM) Platform to generate hypotheses to reveal underlying mechanisms of action and toxicity to help Pfizer prioritize and develop new medicines for treating complex diseases.

"We are pleased to be growing our relationship with Pfizer," said Keith O. Elliston, Ph.D., president and CEO of Genstruct. "We have developed a novel approach to mechanism discovery and this agreement with the world's premier pharmaceutical research and development organization should provide additional validation of our Molecular Epistemics Platform. Through this relationship, we will work with Pfizer scientists to identify mechanisms and biomarkers to improve leads and optimize clinical trial design and execution."

About Genstruct

Founded in 2001, Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders, and inflammation. Genstruct has developed a platform for the discovery of compound mechanisms of action (MOA) and biomarkers called the Molecular Epistemics(TM) Platform. This platform comprises a suite of patent-pending technologies that model and analyze compound MOA and disease mechanisms: the Knowledge Assembly(TM) process which enables rapid, ongoing construction of addressable biological models and the Epistemics Engine(TM) System for mining and refining the models for mechanism discovery and validation. Genstruct engages in internal discovery and external development partnerships that apply the Molecular Epistemics Platform to accelerate and increase the output of drug discovery and development programs. The Company is based in Cambridge, Mass., and its investors include Flagship Ventures of Cambridge, Mass. and A. M. Pappas & Associates of Research Triangle Park, N.C. For more information please visit www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contact
Karen Higgins
A & E Communications for Genstruct
(610) 831-5723
khiggins@aandecomm.com